For Immediate Release DIMERIX PRESENTS AT E&P HEALTHCARE CONFERENCE 2026 MELBOURNE, Australia, 16 September 2026: Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company developing kidney disease treatments, is pleased to advise that CEO and Managing Director, Dr Nina Webster,...
Dimerix Presents at E&P Healthcare Conference 2026
Filed with ASX · · 22 pages · English
Release
In the deck
Story so far
Earlier from Dimerix
- Dimerix DMX-652 Granted Mexican Composition of Matter Patent
- Dimerix Investor Presentation
- S&P DJI Announces September 2026 Quarterly Rebalance
- Dimerix secures a$34 million non-dilutive facility to fund key clinical milestones
- Dimerix Secures A$34 Million Non-Dilutive Funding Facility
Later from Dimerix
- Waiver of Listing Rule 10.1 Granted
- Dimerix Presents at ASX SMIDcaps Conference 2026
- Dimerix Draws Down A$17M Under Non-Dilutive Funding Facility
- Notification of 2026 Annual General Meeting Date
- Notification regarding unquoted securities - DXB
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix